Evidence map›Paper›PMID 35168642›Full record

ArticleJournal of ovarian research2022

A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.

Li Yang, Jinfen Yu, Shuang Zhang, Yisi Shan, Yajun Li, Liugang Xu, Jinhu Zhang, Jianya Zhang

Open access · goldAbstract readValidation Study
In one paragraph

Article in Journal of ovarian research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Li YangZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Jinfen YuZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Shuang ZhangZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Yisi ShanZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Yajun LiZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Liugang XuZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Jinhu ZhangZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China.
Jianya ZhangZhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, 77Changan South Road, Zhangjiagang, 215600, Jiangsu Province, China. y18051093935@126.com.ORCID https://orcid.org/0000-0002-1059-7117
Nanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian mucinous carcinoma is a disease that requires unique treatment. But for a long time, guidelines for ovarian serous carcinoma have been used for the treatment of ovarian mucinous carcinoma. This study aimed to construct and validate nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) in patients with ovarian mucinous adenocarcinoma.

methodsIn this study, patients initially diagnosed with ovarian mucinous adenocarcinoma from 2004 to 2015 were screened from the Surveillance, Epidemiology, and End Results (SEER) database, and divided into the training group and the validation group at a ratio of 7:3. Independent risk factors for OS and CSS were determined by multivariate Cox regression analysis, and nomograms were constructed and validated.

resultsIn this study, 1309 patients with ovarian mucinous adenocarcinoma were finally screened and randomly divided into 917 cases in the training group and 392 cases in the validation group according to a 7:3 ratio. Multivariate Cox regression analysis showed that the independent risk factors of OS were age, race, T_stage, N_stage, M_stage, grade, CA125, and chemotherapy. Independent risk factors of CSS were age, race, marital, T_stage, N_stage, M_stage, grade, CA125, and chemotherapy. According to the above results, the nomograms of OS and CSS in ovarian mucinous adenocarcinoma were constructed. In the training group, the C-index of the OS nomogram was 0.845 (95% CI: 0.821-0.869) and the C-index of the CSS nomogram was 0.862 (95%CI: 0.838-0.886). In the validation group, the C-index of the OS nomogram was 0.843 (95% CI: 0.810-0.876) and the C-index of the CSS nomogram was 0.841 (95%CI: 0.806-0.876). The calibration curve showed the consistency between the predicted results and the actual results, indicating the high accuracy of the nomogram.

conclusionThe nomogram provides 3-year and 5-year OS and CSS predictions for patients with ovarian mucinous adenocarcinoma, which helps clinicians predict the prognosis of patients and formulate appropriate treatment plans.

Indexed as

NomogramsAdenocarcinoma, MucinousAdolescentAdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsArea Under CurveCA-125 AntigenChildFemaleHumansKaplan-Meier EstimateMarital StatusMembrane ProteinsAntineoplastic AgentsCA-125 AntigenMembrane ProteinsMUC16 protein, humanCancer-specific survivalNomogramOvarian mucinous adenocarcinomaOverall survival

Identifiers

PMID35168642
PMCPMC8848949
OpenAlexW4213369439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.